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Abstract
Background:  A marked expansion of the connective tissue population and an abnormal
deposition of extracellular matrix proteins are hallmarks of chronic and acute injuries to liver
tissue. Liver connective tissue cells, also called stellate cells, derived from fibrotic liver have been
thoroughly characterized and correspond phenotypically to myofibroblasts. They are thought to
derive from fat-storing Ito cells in the perisinusoidal space and acquire a contractile phenotype
when activated by tissue injury. In the last few years it has become evident that several peptide
growth factors such as PDGF AA and TGF-β are involved in the development of fibrosis by
modulating myofibroblast proliferation and collagen secretion. The fact that during the
development of chronic fibrosis there is concomitant deposition of collagen, a known inhibitory
factor, and sustained cell proliferation, raises the possibility that stellate cells from chronic liver
fibrosis patients fail to respond to normal physiologic controls.
Methods: In this study we address whether cells from fibrotic liver patients respond to normal
controls of proliferation. We compared cell proliferation of primary human liver connective tissue
cells (LCTC) from patients with liver fibrosis and skin fibroblasts (SF) in the presence of collagens
type I and IV; TGF-β, PDGF AA and combinations of collagen type I and TGF-β or PDGF AA.
Results:  Our results indicate that despite displaying normal contact and collagen-induced
inhibition of proliferation LCTC respond more vigorously to lower concentrations of PDGF AA.
In addition, we show that collagen type I synergizes with growth factors to promote mitogenesis
of LCTC but not SF.
Conclusions: The synergistic interaction of growth factors and extracellular matrix proteins may
underlie the development of chronic liver fibrosis.
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Background
In normal liver, connective tissue cells are rare and mostly
restricted to the periportal and pericentrovenular spaces
and to the Glisson's capsule. A minor population of con-
nective tissue cells is present inside the hepatic lobule, in
the perisinusoidal space. They are known as hepatic stel-
late cells (HSC) and are considered to be one of the major
contributors for fibrogenesis in liver [1]. Chronic and
acute injuries to liver tissue induce a marked expansion of
the connective tissue cells and concomitantly an abnor-
mal deposition of extracellular matrix proteins [2]. Exten-
sive studies of experimental models and humans have
shown that these cells are of the myofibroblast lineage,
characterized by the expression of smooth muscle α-actin
[3-5]. In fact, there is now increasing evidence that are sev-
eral populations of myofibroblasts in the diseased liver in
addition to those derived from HSC [6,7]. The origin of
these cells is still debated. In experimental models, it is
considered that an acute liver injury is followed by activa-
tion and increase of stellate cells, while chronic injuries
elicit activation of similar cells that can be either of lobu-
lar or periportal origin [7]. In humans, extensive primary
periportal fibrosis such as schistosomal fibrosis was
related to expansion of myofibroblasts originating from
the portal vein wall [8], while in cirrhosis resident peri-
portal connective tissue cells, as well as lobular stellate
cells and pericentrovenular cells were reported to convert
into myofibroblasts [3,9,10]. Independently of their ori-
gin, connective tissue cells of human fibrotic and cirrhotic
liver tissues were shown to have homogeneous morpho-
logic characteristics, as well as a specific growth patterns
[11-15].
Recent studies on the mechanisms controlling connective
tissue cell expansion and abnormal collagen deposition
during liver fibrosis have shown that several peptide
growth factors are involved in the development of fibro-
sis. Evidence from in vivo and in vitro studies indicated that
TGF-β has a relevant role in the development of fibrosis,
being a potent regulator of proliferation and of extracellu-
lar matrix protein synthesis [16-18]. TGF-β is highly
expressed in fibrotic regions and overexpression of TGF-β
in animal models results in fibrosis [18,19]. Conversely,
TGF-β antagonists can prevent experimentally induced
fibrosis [20-22]. PDGF AA was shown to have a pivotal
role in controls of normal and pathologic proliferation of
two myofibroblastic cell lineages: mesangial cells in kid-
ney and alveolar smooth muscle cells in lungs [23,24].
On the other hand, it has also been demonstrated in vitro
that the extracellular matrix can in its turn modulate cel-
lular responses to peptide growth factors [25]. In vitro,
fibroblast proliferation can be regulated by the presence
of collagen type I. It has been suggested that collagen
induces a quiescent state by decreasing the responsiveness
to different growth factors [26,27]. An increase in cell den-
sity is also known to inhibit fibroblast proliferation in
vitro. During the development of chronic fibrosis there is
concomitant deposition of collagen and sustained cell
proliferation, raising the possibility that liver connective
tissue cells (LCTC) from chronic liver fibrosis patients fail
to respond to normal physiologic controls.
In this study we addressed the question of whether cells
from fibrotic liver patients respond to normal physiologic
controls of proliferation. We compared the behavior of
primary human LCTC from patients with liver fibrosis
with skin fibroblasts (SF). We compared cell proliferation
in the presence of collagen types I and IV, of TGF-β and
PDGF AA, and in combinations of collagen type I and
TGF-β or PDGF AA. Our results indicate that LCTC
respond more vigorously to lower concentrations of pep-
tide growth factors than SF. Interestingly, collagen type I
synergizes with the growth factors tested in promoting
mitogenesis of LCTC but not of SF. We believe that this
mechanism may underlie the development of chronic
liver fibrosis.
Methods
Cell lines
Liver tissue fragments and skin biopsies were obtained
through collaboration with the University Hospital,
Department of Surgery, Federal University of Rio de
Janeiro (O.M. Vieira, M.D.). An informed consent was
obtained from every patient, and the study was conducted
in agreement with the ethical guidelines of the Federal
University of Rio de Janeiro. Diagnoses were given by the
pathological anatomy service of the hospital. All surgical
liver biopsies were obtained for diagnostic purposes dur-
ing spleno-renal or porto-caval anastomosis. Skin fibrob-
lasts were obtained from the mid-abdominal incision
performed for the surgery. We studied six primary normal
SF lines and ten primary LCTC lines derived from patients
with schistosomal fibrosis or alcoholic cirrhosis.
Biopsies were collected and brought to the laboratory in
chilled Dulbecco's modified Eagle's medium (DMEM)
(Sigma, St. Lois, MO) with 10% fresh human serum and
60 µg/ml of gentamicin (Schering, Rio de Janeiro, Brazil).
They were cut into pieces of approximately 1 mm3,
washed in fresh medium and plated, 6 or 9 pieces per 25
cm2 flask. They were maintained in DMEM supplemented
with 4 g/liter HEPES and 10% fresh human serum, at
37°C in a humid incubator with 5% CO2, 95% air. All the
cultures used in this study were finite cell lines derived
from the primary cultures described above, and were dis-
carded before the 10th passage.
LCTC have been described in detail previously, and com-
pared to skin fibroblasts and vascular smooth muscle cellsBMC Gastroenterology 2004, 4:30 http://www.biomedcentral.com/1471-230X/4/30
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[12,13,15]. They were characterized by electron micros-
copy, immunofluorescence, morphology and prolifera-
tion in culture and ability to contract a collagen matrix.
These established primary cell cultures are homogeneous
in terms of production of smooth muscle α-actin,
fibronectin, collagen I and III, and elements of the base-
ment membrane such as collagen IV and laminin
[12,13,15]. Hence, they can be phenotypically character-
ized as myofibroblasts and different from fibroblasts or
smooth muscle cells.
Serum and growth factors
Fresh human citrated plasma was obtained from the
hemotherapy service of the Hospital dos Servidores do
Estado (Rio de Janeiro, Brazil). Plasma was coagulated
with calcium and sera from several patients were pooled.
Human TGF-β1 and human recombinant PDGF-AA were
purchased from Sigma Chemical Company, St Louis, MO.
TGF-β1 was activated by incubation in bovine serum albu-
min 1 mg/ml and 4 mM HCl.
Preparation of collagen coated dishes
One hundred µl of solutions with varying concentrations
of collagen type I (rat tail tendon collagen, prepared in
our laboratory as previously described [13]) or collagen
type IV (Sigma) were dispensed onto a 12-well or a 96-
well plate and dried under a laminar flow for 24 hr at
room temperature. This procedure allowed us to control
for the exact amount of collagen added to each plate. The
plates used were freshly prepared and were washed three
times in serum free medium.
Proliferation
Cell proliferation was assayed by cell counting and [H3]-
thymidine incorporation. These methods correlated well
with autoradiography results in previous studies [15]. For
the experiments to assay contact inhibition of prolifera-
tion, approximately 1 × 103 cells/cm2 were plated. Each
day, during a period of 8 days, cells were trypsinized and
counted in a hemocytometer and medium was changed
every two days. To assay the proliferative response
induced by growth factors and extracellular matrix pro-
teins cells were trypsinized and plated at a concentration
of 5 × 103 and allowed to adhere for 2 hr in DMEM with
10% serum. Then, cells were starved in serum-free
medium for 18 hr to synchronize the cell population.
When testing for growth factors effects, serum-free
medium was replaced by medium containing 1% serum,
supplemented with the growth factors and 0.5 µCi/ml
[H3]-thymidine. When assessing the effect of extracellular
matrix proteins, serum-free medium was replaced by
medium containing 10% serum. Cells were collected 24
or 32 hr after the stimulus and lysed in 10 N NaOH. The
trichloroacetic acid precipitable material was then spotted
on a filter and counted on a scintillation counter.
Kinetics of thymidine incorporation
Cells were plated at a concentration of 2.5 × 103 per well
(0.5 cm2) in 96 well plates in DMEM with 10% serum.
Cells were allowed to adhere and spread for two hr.
Medium was then replaced with serum-free medium for
24 hr. Subsequently, cells were incubated in different
media containing 1% serum and growth factors. [H3]-thy-
midine (1 µCi/ml) was added at 6, 24, 32 and 40 hr and
incubated for 2 hr. Cells were harvested and processed as
described above.
Adhesion and recovery
To determine cell adhesion on different substrata plates
were prepared with 0.3 mg/ml collagen type I or IV. Cells
were plated on each substratum and the supernatant was
removed at 0, 10, 20, 40 and 60 min and the cells remain-
ing in suspension counted in a hemocytometer. To deter-
mine cell recovery, cells plated after 2 hr were trypsinized
and counted.
Statistical analysis
Difference between the means of various subgroups was
assessed using the Mann-Whitney U-test.
Results
Chronic liver fibrosis is characterized by abnormal prolif-
eration of connective tissue cells. Therefore, we hypothe-
sized that connective tissue cells from fibrotic lesions have
lost normal proliferation controls. By using a series of pri-
mary connective tissue cell lines from skin and from
fibrotic livers, we investigated several parameters of cell
growth in vitro in order to identify potential mechanisms
to explain the excessive proliferation of LCTC during
fibrosis. We observed no differences among the cell lines
obtained from patients with schistosomal fibrosis or alco-
holic cirrhosis, and all the studied primary LCTC lines
were included in a single experimental series. We estab-
lished and characterized 16 primary human cell lines. The
experiments performed were done at or before the tenth
passage and every experiment was performed with at least
two cell lines from each type (LCTC or SF) isolated from
different individuals.
Contact inhibition of proliferation
To assess whether connective tissue cells from fibrotic liv-
ers (LCTC) and normal skin fibroblasts (SF) responded to
contact inhibition of proliferation, we measured cell pro-
liferation during eight days. Both LCTC and SF showed a
comparable pattern of growth and reached a plateau at a
similar cell density (Figure 1A,1B). Reproducibly, LCTC
declined in number after reaching a maximal density (Fig-
ure 1B, day 8). To confirm these results, we measured
[H3]-thymidine incorporation in various cell densities
(Figure 1C). Both LCTC and SF showed maximum [H3]-
thymidine incorporation at the same cell density (1 × 104/BMC Gastroenterology 2004, 4:30 http://www.biomedcentral.com/1471-230X/4/30
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cm2) and a marked decline at higher densities. We also
examined the response of both cell types to increasing
concentrations of fresh human serum. Both SF and LCTC
reached maximum proliferation, as measured by [H3]-
thymidine incorporation at 20% serum (not shown). In
conclusion, primary SF and LCTC were similarly respon-
sive to normal contact inhibition of proliferation and
serum concentration, although SF seemed to respond
more efficiently to contact inhibition.
The effects of extracellular matrix
Despite the abnormal deposition of extracellular matrix in
chronic fibrotic livers, LCTC continuously proliferate sug-
gesting that these cells are not responsive to normal inhi-
bition of proliferation by collagen I. To determine the
influence of the extracellular matrix on LCTC, we ana-
lyzed DNA synthesis in the presence of collagen type I and
type IV, two major components of extracellular matrix in
fibrotic livers. Collagen type I inhibited DNA synthesis in
a dose-dependent manner, as measured by [H3]-thymi-
dine incorporation in LCTC and SF (Figure 2A,2B). In SF,
[H3]-thymidine incorporation at the highest collagen con-
centration was approximately 30% of the control, suggest-
ing that this cell type is more susceptible to collagen-
mediated inhibition of proliferation. However, the level
of the inhibition was variable among the studied patients,
and a less marked reduction, (~50%) was observed in SF
derived from some of the studied cases (not shown). We
did not observe any change in cell morphology dependent
upon the substrate.
The question of whether the difference observed between
collagen-coated and plastic plates resulted from an altera-
tion in kinetics of cell cycle progression or to an actual
block in DNA synthesis was addressed in the following
experiment. After serum-mediated activation of quiescent
cells, the cultures were pulsed with [H3]-thymidine for 2
hr, at 6, 20, 26, 32 and 40 hr. [H3]-thymidine incorpora-
tion reached its peak at 32 hours after activation in control
experiments (plated on plastic), and cells plated on colla-
gen-coated plates did not show any delayed peak, demon-
strating that the effect of collagen was not delaying the
progression of cell cycle but blocking DNA synthesis (Fig-
ure 2C). These results indicate that LCTC are responsive to
normal inhibition of proliferation mediated by collagen I.
Next, we asked whether collagen type IV could also influ-
ence the proliferation of the studied cells. Even at high
concentrations (90 µg/cm2), collagen type IV did not
induce any significant change on [H3]-thymidine incorpo-
ration in two LCTC cell lines, neither in two SF cell lines
(not shown). Again, no difference in morphology was
noted.
To rule out the possibility that the results were being
masked by differential adhesion to collagen or differential
cell recovery when measuring the [H3]-thymidine incor-
poration, we monitored cell adhesion on plastic, on colla-
gen type I and on collagen type IV. Although by 10 min
there were a significantly less cells attached on collagen IV,
by 40 min the same number of cells had attached to the
plates in all substrates (Figure 2C, right panel). These
results rule out the possibility that lower [H3]-thymidine
incorporation found in cells plated on collagen I was due
to differential adhesion, since our experiments allowed 2
hr for attachment. We also counted cell numbers on the
samples recovered for scintillation counting and found it
to be comparable (Figure 2C, right panel), thus ruling out
the possibility that the difference was due to differential
recovery. Taken together these results indicate that LCTC
Contact inhibition of proliferation Figure 1
Contact inhibition of proliferation. A. Proliferation of 
normal human skin fibroblasts (SF) in vitro. B. Proliferation 
of human liver connective tissue cells (LCTC). Cells were 
plated at 1 × 103 cells/cm2. Each day, during a period of 8 
days, cells were trypsinized and counted in a hemocytometer 
(n = 3). Medium containing 10% serum was replaced every 
two days. C. [H3]-Thymidine incorporation in SF and LCTC 
at increasing cell density (n = 4).
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are responsive to normal inhibition of proliferation medi-
ated by collagen I in a manner similar to that of normal
SF.
Effects of PDGF AA and TGF-β on proliferation
To investigate the effects of PDGF AA we starved cells for
18 hr and stimulated them with increasing concentrations
of PDGF AA. As shown in Figure 3A, LCTC were more sen-
sitive to lower concentrations of the growth factor (5, 10
and 20 ng/ml), reaching a peak at 10 ng/ml. Although
reaching the same level of stimulation at 40 ng/ml, SF
were less sensitive to PDGF AA at lower concentrations.
PDGF AA did not affect timing of cell cycle progression,
since cells in the presence and in the absence of PDGF AA
displayed a peak of [H3]-thymidine incorporation at 26 hr
after release in medium containing serum and factors
(results not shown). In conclusion, LCTC appear to be
more sensitive to lower concentrations of PDGF AA.
Collagen-mediated inhibition of proliferation Figure 2
Collagen-mediated inhibition of proliferation. A. Cell proliferation of LCTC plated on increasing collagen concentration 
as measured by [H3]-Thymidine incorporation (n = 4). Note inhibition of incorporation in a dose-dependent manner. B. Cell 
proliferation of SF plated on increasing collagen concentration as measured by [H3]-Thymidine incorporation (n = 4). Note 
inhibition of incorporation in a dose-dependent manner. (*) denotes significant difference from control; p ≤ 0.05. C. Left panel. 
Kinetics of DNA synthesis of LCTC comparing growth on plastic (empty circles) and on collagen (filled circles) (n = 4). Right 
panel, top. Adhesion of cells plated on plastic (filled circles), collagen IV (empty triangles) and collagen I (empty squares) (n = 3). 
Right panel, bottom. Recovery of cells from plastic or collagen I (n = 4).
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To test the responsiveness of LCTC and SF to TGF-β, cells
were starved overnight and stimulated with increasing
concentrations of acid-activated TGF-β. In Figure 3B we
note that at lower concentrations, stimulation of LCTC
and SF is comparable. However, higher concentrations of
TGF-β (0.1 ng/ml) seemed to be less effective in promot-
ing mitogenesis of SF. Interestingly, at the highest concen-
tration (1 ng/ml) TGF-β was inhibitory to SF but still
highly stimulatory for LCTC. When we analyzed the kinet-
ics of thymidine incorporation during TGF-β treatment
(Figure 3C,3D) we observed a second delayed peak of
DNA synthesis at 40 hr (Figure 3C and 3D, arrow). In
smooth muscle cells this second delayed peak has been
shown to be due to a PDGF AA autocrine loop [28]. While
in LCTC the second peak was 85% of the first peak, in SF
it was slightly under 50%. These results indicate that TGF-
β can induce a prolonged and strong induction of DNA
synthesis in LCTC even at concentrations that are inhibi-
tory for SF. In this set of experiments we were able to com-
pare matched LCTC and SF from the same patient. Our
Mitogenic effects of PDGF AA and TGF-β on SF and LCTC Figure 3
Mitogenic effects of PDGF AA and TGF-β on SF and LCTC. A. Effect of increasing PDGF AA concentrations on 
growth of LCTC (black bars) and SF (gray bars) (n = 4). B. Effect of increasing concentrations of TGF-β on growth of LCTC 
(black bars) and SF (gray bars) (n = 4). (*) denotes significant difference between SF and LCTC; p ≤ 0.05. C. Kinetics of DNA 
synthesis in LCTC as measured by [H3]-thymidine incorporation in the presence (filled circles) and absence (empty circles) of 
TGF-β (n = 4). Note second delayed peak of incorporation at 40 hr (black arrow). D. Kinetics of DNA synthesis in SF as meas-
ured by [H3]-thymidine incorporation in the presence (filled circles) and absence (empty circles) of TGF-β (n = 4). Note the 
absence of the second delayed peak of incorporation at 40 hr (black arrow).
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results indicate that the observed differences between
LCTC and SF are not due to individual variation or genetic
background.
Synergy of extracellular matrix and growth factors
Next, we assessed the interplay between growth factors
and the extracellular matrix on the stimulation of prolifer-
ation. We compared proliferation of cells cultured on col-
lagen film using the highest inhibitory concentration (42
µg/cm2; Figure 2) and cultured on plastic. Initially, we
treated cells with 10 ng/ml of PDGF AA in the presence
and absence of collagen after 24 hr (Figure 4A). Both
LCTC and SF were efficiently inhibited by collagen, in
accordance with the experiments in Figure 2A and 2B, per-
formed with different cell lines. In the absence of colla-
gen, PDGF AA stimulated proliferation comparable to
that obtained in Figure 3A and 3B. These conditions pro-
vide an internal control to distinguish effects that are cell
type-specific from individual variations. Surprisingly,
PDGF AA was able to override the collagen-mediated inhi-
bition only in LCTC and not in SF.
Next, cells were stimulated with TGF-β (Figure 4B) and
proliferation measured. Since there was a possibility that
the autocrine loop could induce a late response, we
assessed [H3]-thymidine incorporation at 40 hr. (Figure
4B). Collagen inhibited these cell lines as in previous
experiments with LCTC and SF cell lines. TGF-β alone had
little effect on proliferation. However, similarly to the
experiment with PDGF AA, TGF-β was not only able to
override the collagen-mediated inhibition but showed a
synergistic effect only in LCTC. SF were not able to escape
inhibition mediated by collagen.
Discussion
Injuries to liver tissue usually involve transient or long-
term development of fibrosis. In acute injuries, fibrotic tis-
sue is frequently reabsorbed and normal tissue architec-
ture is restored. In cases when the primary agent or the
secondary pathogenic mechanisms are persistent, the
fibrotic reaction can be perpetuated causing a severe
impairment of organ function [1]. It is therefore
important to identify the factors that are involved in this
perpetuation in order to devise more efficient preventive
measures and therapies. However, there is a dearth of
knowledge about the behavior of the human LCTC iso-
lated from fibrotic livers. In fact, most studies done to date
used LCTC cells from experimental models such as rats
and mice and the few studies dealing with myofibroblasts
from human liver derived the cells from normal tissue.
In order to evaluate the hypothesis that LCTC from
fibrotic livers had lost control of proliferation we investi-
gated their growth in tissue culture. Contact inhibition of
proliferation is a characteristic of normal cells and is lost
in neoplastic cell lines. Our results showed that LCTC
respond normally to contact inhibition of proliferation.
Collagen type I, which is the predominant extracellular
matrix protein deposited during hepatic fibrogenesis [2],
has been shown to be a potent inhibitor of mesenchymal
cell proliferation [26,29,30]. Since the perpetuated prolif-
eration of LCTC is a hallmark of chronic liver diseases, it
was conceivable that these cells had lost normal collagen-
mediated inhibition. However, our results indicate that
LCTC derived from fibrotic livers are responsive to colla-
gen I to an extent comparable to normal skin fibroblasts.
Interaction between peptide growth factors and extracellular  matrix Figure 4
Interaction between peptide growth factors and 
extracellular matrix. A. Effects of PDGF AA on the 
growth of LCTC (black bars) and SF (gray bars) plated on 
collagen or plastic (n = 4). B. Effects of TGF-β on the growth 
of LCTC (black bars) and SF (gray bars) plated on collagen or 
plastic (n = 3). (*) denotes significant difference between SF 
and LCTC; p ≤ 0.05.
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In addition, collagen IV a major component of basement
membranes did not affect the growth of either cell type
studied.
While recent evidence from rat vascular smooth muscle
cells indicates that PDGF AA promotes only protein syn-
thesis without activation of DNA synthesis [31], we dem-
onstrate that PDGF AA is active as a mitogen for human
LCTC. These results are in accordance with previous data
using connective tissue cells derived from normal liver
[32]. Interestingly, the same authors have found that in
fibrotic livers there is marked increase in the expression of
both PDGFα receptor and its ligand PDGF AA [33]. Taken
together, these results strengthen the notion that PDGF-
AA is an important mediator of connective tissue expan-
sion during liver fibrosis.
Although generally agreed to contribute to the fibrogenic
process by upregulating expression of genes encoding
extracellular matrix proteins, a role for TGF-β in promot-
ing mitogenesis has emerged in the last few years. TGF-β
displayed a bi-phasic curve with low concentrations stim-
ulating and higher doses inhibiting the proliferation of SF.
On the other hand, TGF-β was a potent mitogenic stimu-
lus for LCTC even at high concentrations. Interestingly, it
has been shown that TGF-β also stimulates an additional
delayed growth response mediated by an autocrine loop
of PDGF AA [28], which we observed only in LCTC.
One surprising outcome of this study was that not only
the peptide growth factors tested were able to override the
collagen-mediated inhibition, but that they were also able
to synergize with the extracellular matrix. Since the colla-
gen we used was a crude preparation from rat tail tendon
we cannot rule out the possibility that the observed effect
may depend on other associated proteins that are known
to be accessory factors in promoting more efficient ligand-
binding to the receptor. These results reinforce the notion
that connective tissue cells can be therapeutically control-
led using a strategy to inhibit the action of peptide growth
factors.
It is well known that continuous presence of the injury
agent determines the evolution of the disease, favoring its
progression and perpetuation (establishment of a
permanent scar tissue). On the other hand, it is largely
unclear which are the other physiologic determinants for
disease evolution. Genetic background is known to influ-
ence the development of hypertrophic cheloid skin scars
as well as the outcome of schistosomal liver fibrosis [34].
In experiments in which we were able to use matched
LCTC and SF from the same individual our results suggest
that tissue origin was consistently more important than
the genetic background, since LCTC behaved differently
from the same-patient's SF but similarly to LCTC from dif-
ferent individuals.
Conclusions
The results obtained in this study using human primary
liver connective tissue cells suggest a plausible scenario for
the development of liver fibrosis. Stellate quiescent cells
are triggered to proliferate by high molecular weight
serum factors [15] and may be subjected to a positive
autocrine and paracrine feedback loop of growth factor
stimulation. Whereas under normal conditions connec-
tive tissue cells are kept under strict check by the extracel-
lular matrix, PDGF AA and TGF-β are capable of not only
overriding the inhibitory effect caused by collagen type I
on LCTC but also synergize to provide a stronger stimulus
for proliferation. This interplay of extracellular signals
may underlie the development of irreversible liver
fibrosis.
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